# US 2024/0180479 A1 · Treatment of Parkinson's Disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0180479 A1
- Document ID: US20240180479A1
- Status: Published application
- Kind: A1
- Application number: 18/279,408
- Filed: 2022-03-08
- Published: 2024-06-06
- Earliest claimed: 2021-03-08
- Assignees: Prothena Biosciences Limited; Hoffmann-La Roche Inc.
- Applicants: Prothena Biosciences Limited; Hoffmann-La Roche Inc.
- Inventors: Gennaro Pagano
- Web page: https://patentgrep.com/patent/US20240180479A1

## CPC

- C07K 16/247: {IL-4}
- A61B 5/112: {Gait analysis}
- A61B 5/1124: {Determining motor skills}
- A61B 5/4082: {Diagnosing or monitoring movement diseases, e.g. Parkinson, Huntington or Tourette}
- A61B 5/4848: {Monitoring or testing the effects of treatment, e.g. of medication}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/16: Anti-Parkinson drugs
- C07K 16/18: against material from animals or humans
- A61B 5/1101: {Detecting tremor}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides a method of treating, preventing or ameliorating Parkinson's disease with Prasinezumab; wherein providing the patient with a mobile device programmed to receive and transmit data acquired to measure passive and/or active movement of the patient (b) collecting data transmitted from the mobile device; and (c) comparing the data acquired from the patient with control data to assess presence or extent of movement deficits in the subject and/or monitoring the data acquired from the patient for a period of time sufficient to identify changes in the patient's active or passive motor function.

## Claims

### Claim 1

A method for monitoring the motor function of a patient that has Parkinson's Disease (PD) or is at risk for PD who has been administered Prasinezumab, the method comprising.
(a) providing the patient with a mobile device programmed to receive and transmit data acquired from sensors internal and/or external to the mobile device that measure passive and/or active movement of the patient or a mobile device application programmed to receive and transmit data acquired from sensors internal and/or external to the mobile device that measure passive and/or active movement of the patient;
(b) collecting data transmitted from the mobile device; and
(c) comparing the data acquired from the patient with control data to assess presence or extent of movement deficits in the subject and/or monitoring the data acquired from the patient for a period of time sufficient to identify changes in the patient's active or passive motor function.

### Claim 2 (depends on 1)

The method of claim 1, wherein the sensors transmit data acquired from active movement of the patient.

### Claim 3 (depends on 1, 2)

The method of any of claim 1 or 2, wherein the mobile device is programmed to receive and transmit data from external sensors attached to upper and lower limbs of the patient.

### Claim 4 (depends on 1, 2, 3)

The method of any of claims 1-3, wherein the mobile device acquires data from sensors on the upper and lower limbs of the subject.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any of claims 1-4, wherein the mobile device is carried by the subject and acquires data from an internal sensor.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any of claims 1-5, wherein the movement comprises tapping the device, sitting and standing.

### Claim 7 (depends on 1, 2, 3, 4, 5)

The method of any of claims 1-5, wherein the sensors measure one or more of the following features of the patient's movement:
(a) median gesture power of passively monitored gestures:
(b) median turn speed in U-turn test and passively monitored gait,
(c) jerk in balance test,
(d) mel frequency cepstrum 2 in speech test,
(e) voice jitter in sustained phonation,
(f) number correct in Symbol Digit Modalities Test.
(g) speeded tapping variability,
(h) maximum speed of hand-turning,
(i) spiral celerity in draw-a-shape task, and
(j) median squared energy in rest and postural tremor tasks.

### Claim 8 (depends on 7)

The method claim 7, wherein the independently measure movement from the least affected side and the most affected side of the patient.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any of claims 1-8, wherein the data collected from the device is compared the patient's MDS-UPDRS score.

### Claim 10 (depends on 9)

The method of claim 9, wherein the MDS-UPDRS score comprises of one of MDS-UPDRS Part I, MDS-UPDRS Part II, or UPDRS Part III.

### Claim 11 (depends on 10)

The method of claim 10, wherein the MDS-UPDRS score comprises UPDRS Part III.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1-11, further comprising administering a regimen Prasinezumab to the patient.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method of any one of claims 1-12, wherein the regimen of Prasinezumab comprises 1000-5000 mg of Prasinezumab at intervals of 3 to 5 weeks.

### Claim 14 (depends on 13)

The method of claim 13, wherein Prasinezumab is administered intravenously.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method of any of claims 1-14, further comprising administering to the patient a MAO-B inhibitor.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any of claims 1-15, wherein the patient is treatment naïve, was diagnosed as having PD in the last two years, or was previously treated with a MAO-B inhibitor.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of any of claims 1-16, wherein the patient has a weight greater than 65 kg and is administered a dose of 4500 mg Prasinezumab once every 4 weeks.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of any of claim 1-16, wherein the patient has a weight less than 65 kg and is administered a dose of 3500 mg Prasinezumab once every 4 weeks.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of any of claims 1-16, wherein the patient is administered a dose of 1500 mg antibody every 4 weeks.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of any of claims 1-19, wherein the patient is administered Prasinezumab once every 4 weeks for at least 52 weeks.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any of claim 1-20 wherein the period of time sufficient to identify changes in the patient's active or passive motor function comprises 4-52 weeks.

### Claim 22 (depends on 21)

The method of claim 21, wherein the period of time is 4 weeks, 8 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 42 weeks, 46 weeks or 52 weeks.
